JL19001
/ Jecho Biopharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 20, 2026
JL19001-NMIBC: A Phase I/II Study of JL19001 Injection Alone or in Combination With BCG in Subjects With High Risk Non-Muscle Invasive Bladder Cancer.
(clinicaltrials.gov)
- P1 | N=18 | Not yet recruiting | Sponsor: Jecho Biopharmaceuticals Co., Ltd.
New P1 trial • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1